سعر ميلناسيب 50مجم 30 كبسولة 2022

Milnacipran hydrochloride 50 mg hard gelatin capsules, pack of 30 (Milnacip, Andalous Pharma).

• Treatment of major depressive episodes in adults.Population: AdultsBase de Données Publique des Médicaments (ANSM, France)
• Management of fibromyalgia in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Very common adverse effects: headache and nausea.International label, same formulation · Base de Données Publique des Médicaments (ANSM, France)
• Most frequent adverse reactions (5% or more and at least twice placebo) in fibromyalgia trials: constipation, hot flush, hyperhidrosis, vomiting, palpitations, increased heart rate, dry mouth and hypertension; nausea was the most common reason for withdrawal.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Contraindicated with irreversible non-selective MAO inhibitors, selective MAO-B inhibitors, digitalis glycosides and 5-HT1D agonists (triptans); during breastfeeding; in uncontrolled hypertension and severe or unstable coronary disease; hypersensitivity. Generally not recommended with parenteral adrenaline/noradrenaline, clonidine and related drugs, selective MAO-A inhibitors, and in prostatic hypertrophy or other genitourinary disorders.International label, same formulation · Base de Données Publique des Médicaments (ANSM, France)
• Contraindicated with MAO inhibitors intended to treat psychiatric disorders (or within 5 days of stopping milnacipran, or within 14 days of stopping an MAOI); do not start in patients treated with linezolid or intravenous methylene blue.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning: antidepressants increase the risk of suicidal thoughts and behaviours in children, adolescents and young adults; monitor for clinical worsening and emergence of suicidal thoughts.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Serotonin syndrome (risk increased with triptans, tricyclics, fentanyl, tramadol, lithium, St John's wort and other serotonergic drugs); increased blood pressure and heart rate; seizures; hepatotoxicity; discontinuation syndrome; hyponatraemia; abnormal bleeding (with NSAIDs, aspirin, anticoagulants); activation of mania; dysuria/urinary hesitancy; angle-closure glaucoma; avoid substantial alcohol use.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Digitalis glycosides (digoxin)Contraindicated combination in the French SmPC (risk of potentiated haemodynamic effects, particularly with parenteral digoxin).Base de Données Publique des Médicaments (ANSM, France)
• Parenteral adrenaline/noradrenaline; clonidine and related drugsNot recommended in the French SmPC (risk of hypertensive episodes with adrenaline/noradrenaline; reduced antihypertensive effect of clonidine).Base de Données Publique des Médicaments (ANSM, France)
• MAO inhibitors (including linezolid and intravenous methylene blue)Increased risk of serotonin syndrome; concomitant use is contraindicated (allow 14 days after an MAOI and 5 days after milnacipran).DailyMed (U.S. National Library of Medicine)

• Pregnancy: data are insufficient; as a precaution, avoid use during pregnancy.International label, same formulation · Base de Données Publique des Médicaments (ANSM, France)
• Data in pregnancy are insufficient to evaluate drug-associated risk; SNRI exposure in the month before delivery is associated with a less than 2-fold increase in postpartum haemorrhage. Neonates exposed late in the third trimester have developed complications requiring prolonged hospitalisation.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is contraindicated during treatment.International label, same formulation · Base de Données Publique des Médicaments (ANSM, France)

• Milnacipran hydrochloride: Inhibits neuronal reuptake of norepinephrine and serotonin (about 3-fold more potent for norepinephrine in vitro) without direct effect on dopamine uptake; its mechanism in fibromyalgia is unknown.